Central African RepublicTuberculosis profile
Population  2014 4.8 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.3 (1.6–3.1) 48 (34–65)
Mortality (HIV+TB only) 3.1 (2.2–4.1) 64 (46–86)
Prevalence  (includes HIV+TB) 21 (12–33) 435 (241–683)
Incidence  (includes HIV+TB) 18 (16–20) 375 (333–420)
Incidence (HIV+TB only) 7.6 (5.9–9.4) 157 (124–195)
         
Case detection, all forms (%) 57 (50–64)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.4 (0–2.5) 11 (6.2–16)
MDR-TB cases among notified pulmonary
TB cases
32 (0–200) 42 (24–60)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 5 106   383
Pulmonary, clinically diagnosed 3 012   0
Extrapulmonary 1 685   0
       
Total new and relapse 10 186    
Previously treated, excluding relapses 0    
Total cases notified 10 186    
Among 4 885 new cases:
206 (4%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 92 (2%) 0 (0%) 92
Laboratory-confirmed RR-/MDR-TB cases     40
Patients started on MDR-TB treatment ***     21
TB/HIV 2014 Number (%)
TB patients with known HIV status 5 201 (51)
HIV-positive TB patients 1 781 (34)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (70) 4 400
Previously treated cases registered in 2013 (62) 514
HIV-positive TB cases, all types, registered in 2013 (62) 1 972
RR-/MDR-TB cases started on second-line treatment in 2012 (81) 16
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 2.1
Drug susceptibility testing (per 5 million population) 1.0
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions) 1.7
% Funded domestically 25%
% Funded internationally 17%
% Unfunded 58%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-03 Data: www.who.int/tb/data